Loss of function mutations in HARS cause a spectrum of inherited peripheral neuropathies by Safka Brozkova, Dana et al.
Loss of function mutations in HARS cause a
spectrum of inherited peripheral neuropathies
Dana Safka Brozkova,1 Tine Deconinck,2,3 Laurie Beth Griffin,4,5 Andreas Ferbert,6
Jana Haberlova,1 Radim Mazanec,7 Petra Lassuthova,1 Christian Roth,6
Thanita Pilunthanakul,8 Bernd Rautenstrauss,9,10,† Andreas R. Janecke,11
Petra Zavadakova,12 Roman Chrast,12 Carlo Rivolta,12 Stephan Zuchner,13
Anthony Antonellis,4,14,15 Asim A. Beg,8 Peter De Jonghe,2,3,16 Jan Senderek,10,*
Pavel Seeman1,* and Jonathan Baets2,3,16,*
†Deceased.
*These authors contributed equally to this work.
Inherited peripheral neuropathies are a genetically heterogeneous group of disorders characterized by distal muscle weakness and
sensory loss. Mutations in genes encoding aminoacyl-tRNA synthetases have been implicated in peripheral neuropathies, suggesting
that these tRNA charging enzymes are uniquely important for the peripheral nerve. Recently, a mutation in histidyl-tRNA
synthetase (HARS) was identiﬁed in a single patient with a late-onset, sensory-predominant peripheral neuropathy; however, the
genetic evidence was lacking, making the signiﬁcance of the ﬁnding unclear. Here, we present clinical, genetic, and functional data
that implicate HARS mutations in inherited peripheral neuropathies. The associated phenotypic spectrum is broad and encom-
passes axonal and demyelinating motor and sensory neuropathies, including four young patients presenting with pure motor
axonal neuropathy. Genome-wide linkage studies in combination with whole-exome and conventional sequencing revealed four
distinct and previously unreported heterozygous HARS mutations segregating with autosomal dominant peripheral neuropathy in
four unrelated families (p.Thr132Ile, p.Pro134His, p.Asp175Glu and p.Asp364Tyr). All mutations cause a loss of function in
yeast complementation assays, and p.Asp364Tyr is dominantly neurotoxic in a Caenorhabditis elegans model. This study dem-
onstrates the role of HARS mutations in peripheral neuropathy and expands the genetic and clinical spectrum of aminoacyl-tRNA
synthetase-related human disease.
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Introduction
Inherited peripheral neuropathies (IPNs) represent a
common, heterogeneous group of disorders that affect
about 1 in 2500 individuals worldwide (Skre, 1974). A
common feature of these diseases is progressive, length-
dependent axonal degeneration of the peripheral nervous
system resulting in impaired motor and sensory function
in the distal extremities. IPNs are clinically subdivided
based on the involvement of different types of peripheral
nerve ﬁbres. The most common type is hereditary motor
and sensory neuropathy (HMSN), also known as Charcot–
Marie–Tooth (CMT) disease, which affects both motor and
sensory ﬁbres. Less frequent subtypes display more selective
involvement of nerve ﬁbres and include hereditary motor
neuropathy (HMN) and hereditary sensory and autonomic
neuropathy (HSAN). The common HMSN/CMT group is
further classiﬁed based on electrophysiological studies with
motor nerve conduction velocities in the median nerve
538m/s (normal 449m/s) indicating demyelinating neur-
opathy (CMT1 or HMSN-I) and nerve conduction veloci-
ties 438m/s indicating axonal neuropathy (CMT2 or
HMSN-II) (Harding and Thomas, 1980). In addition, an
intermediate group is deﬁned as having nerve conduction
velocities between 25 and 45m/s among patients in the
same family (Baets et al., 2014). Interestingly, IPNs display
a high level of clinical heterogeneity, even among patients
that carry an identical genetic lesion.
The genetic diversity of IPN is extensive with 475 genes
identiﬁed to date (Baets et al., 2014). The transmission of
the disease can be autosomal dominant, autosomal reces-
sive, or X-linked. Dominantly inherited CMT1 is the most
common type and also the easiest to diagnose genetically
with mutations in three loci accounting for at least 80% of
cases (Saporta et al., 2011; Rossor et al., 2013). In con-
trast, for axonal forms (CMT2) the genetic cause is only
found in  25% of patients because there are no major
gene(s) accounting for a substantial proportion of patients
(with the possible exception of mitofusin 2, MFN2), and
the locus and allelic heterogeneity of CMT2 is extensive
with many genes still undiscovered (Murphy et al., 2012).
Aminoacyl-tRNA synthetases (ARSs) are ubiquitously
expressed, essential enzymes that charge tRNA molecules
with cognate amino acids—the ﬁrst step of protein transla-
tion (Antonellis and Green, 2008). To date, mutations in
six genes encoding ARSs have been identiﬁed in patients
with IPN phenotypes (Antonellis et al., 2003; Jordanova
et al., 2006; Latour et al., 2010; McLaughlin et al.,
2010; Gonzalez et al., 2013a; Vester et al., 2013). Three
of these genes have been convincingly implicated in disease
via linkage analysis, with multiple families and patients
described in independent studies: (i) glycyl-tRNA synthetase
mutations (GARS) cause CMT2D and HMN5A (Antonellis
et al., 2003); (ii) tyrosyl-tRNA synthetase mutations
(YARS) cause an intermediate form of CMT (DI-CMTC)
(Jordanova et al., 2006); and (iii) alanyl-tRNA synthetase
mutations (AARS) cause CMT2N and also a form of HMN
(Latour et al., 2010; Zhao et al., 2012). Interestingly,
extensive functional studies have shown that disease-
associated ARS mutations cause a loss-of-function effect
in tRNA charging and yeast viability assays, suggesting
that peripheral nerves are uniquely sensitive to tRNA char-
ging deﬁcits (Wallen and Antonellis, 2013).
Recently, a p.Arg137Gln variant in the histidyl-tRNA
synthetase gene (HARS) was found by whole exome
sequencing in an isolated patient with a sporadic, late-onset
predominantly sensory axonal neuropathy (Vester et al.,
2013). While functional studies in yeast revealed that the
variant behaved similarly to other disease-implicated ARS
variants, the lack of convincing genetic ﬁndings and the
detection of the variant in the general population made it
impossible to conclude that this was a disease-causing mu-
tation (Vester et al., 2013). Here, we present 23 patients
from four unrelated families with HARS mutations that
segregate with axonal or intermediate neuropathy pheno-
types. Our functional studies show that all identiﬁed
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mutations are unable to support viability in yeast comple-
mentation assays and that one mutation is dominantly
toxic in a worm model system. Combined, our data clearly
establish HARS as a neuropathy-associated locus and
further expand the genetic and phenotypic spectrum of
ARS-related human disease.
Patients and methods
Patients
In total, 23 patients from four unrelated families with a dom-
inantly inherited peripheral neuropathy are described (Fig. 1).
The Ethical Review Boards of the participating institutions
approved this study. All patients or their legal representatives
signed informed consent prior to enrolment.
Linkage analysis
To deﬁne the molecular genetic basis of the disease in Families
A and D, a whole genome scan using single nucleotide poly-
morphism (SNP) arrays was carried out. Genomic DNA sam-
ples from patients and unaffected relatives were hybridized to
GeneChip Human Mapping NspI 250 K arrays (Family A,
seven individuals) and GeneChip Human Mapping 50 K
arrays (Family D, 12 individuals) (Affymetrix) according to
the manufacturer protocols. Genotypes were called using
GeneChip Genotyping Analysis Software (Version 4.1) and
default thresholds. To identify the linkage regions, the para-
metric multipoint logarithm of the odds (LOD) scores and
haplotypes were obtained using a subset of SNPs (distance
between markers 450 kb and heterozygosity 40.15) with
the MERLIN program (v 1.1.2) with the assumption of an
autosomal dominant mode of inheritance and fully penetrant
model (Abecasis et al., 2002).
For Family B, an in-house developed multiplex genome-scan
panel was used consisting of 422 polymorphic short tandem
repeat (STR) markers, subsequently PCR ampliﬁed with ﬂuor-
escently labelled primers and size-separated on an ABI3730xl
DNA Analyzer. Results were scored with an in-house
developed software program, Local Genotype Viewer (LGV).
Two-point parametric linkage analysis was calculated with
EasyLINKAGE software package under a fully penetrant auto-
somal dominant model, equal female/male recombination
rates, and a disease frequency of 0.0001.
Sanger sequencing
Prior to linkage analysis, candidate gene sequencing, or whole-
exome sequencing, the chromosome 17 duplication (CMT1A)
was excluded in all four families. Subsequently, various sets of
IPN associated genes were tested negative in these families:
GJB1, MPZ, BSCL2, NEFL, MFN2, HSP22, HSP27, RAB7,
GARS, YARS, DNM2, and TRPV4 in Family A; MPZ,
PMP22, GJB1, GARS, AARS, and GDAP1 in Family B;
PMP22 in Family C; GJB1, MPZ, HSP22, HPS27, SETX,
and BSCL2 in Family D.
For the index patient of Family A, all 13 coding exons and
adjacent exon-intron boundaries of HARS were ampliﬁed as
well as a cohort of 61 index patients with genetically unre-
solved HMN (primers available upon request). To validate
whole-exome sequencing results (Families B, C and D) and
to demonstrate segregation, the mutated exons of HARS
were Sanger sequenced in all available individuals. Primer
pairs were designed with the Primer3 program (sequences
available upon request) (Rozen and Skaletsky, 2000). Total
Figure 1 Pedigrees of the families with HARSmutations. Female family members are indicated with a circle and male family members are
indicated by squares. Filled symbols indicate affected individuals, while empty symbols indicate unaffected individuals. The number of the individual
is shown in Arabic numerals if the DNA was available for genotyping.
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genomic DNA was PCR ampliﬁed and PCR products were
bi-directionally sequenced using the BigDye Terminator
v3.1 cycle sequencing kit (Applied Biosystems). Fragments
were separated on an ABI3730xl and ABI 3130 Genetic
Analyzer (Applied Biosystems) and analysed with SeqManTM
II Software (DNAstar Inc.) and Mutation Surveyor
(Softgenetics).
Whole-exome sequencing
Index patients from Families B and C and two distant relatives
from Family D (Subjects IV.1 and IV.6) were selected for
whole-exome sequencing. Exome capture was performed
using the Agilent SureSelect Human All Exon V5 kit
(50Mb), followed by sequencing on a HiSeq 2000 platform
(Illumina). Sequence alignment was performed using the
BWA-v0.5.9rc1 tool. GATK-v1.4-37 was used for variant
calling. Further data analysis was performed in the Genomes
Management Application database (GEM-app) (Gonzalez
et al., 2013b). Variants were ﬁltered for the regions with sug-
gestive linkage for Families B and D, no occurrence in the
normal population [absent in the Exome Variant Server
(EVS)], predicted impact on the encoded protein (missense,
nonsense, frame shift, inframe indels and essential splice vari-
ants), conservation [Genomic Evolutionary Rate Proﬁling
(GERP) score 4 4, or PhastCons score 4 0.9, or PhyloP
Score 4 1.5], and predicted damaging amino acid substitution
[at least in one: SIFT, PolyPhen-2, MutationTaster, Mutation
Assessor, Likelihood Ratio Test (LRT), Functional Analysis
through Hidden Markov Models (FATHMM)], and quality
(GATK GQ score 4 75). An overview of the general outcome
after performing whole-exome sequencing (number of reads,
coverage etc.) can be found in Supplementary Table 1.
Conﬁrmation of the possible pathogenic variants and segrega-
tion analysis in all available family members was performed
using Sanger sequencing.
Yeast complementation assays
Yeast complementation assays were performed as previously
described (Vester et al., 2013). Brieﬂy, mutation-containing
oligonucleotides were designed to model the p.Thr132Ile,
p.Thr132Ser, p.Pro134His, p.Asp175Glu, or p.Asp364Tyr
HARS missense variants in the yeast orthologue HTS1. The
QuickChange II XL Site-Directed Mutagenesis Kit
(Stratagene) was used (per manufacturer’s instructions) to
mutate the HTS1 locus in a pDONR221 Gateway entry
clone (Invitrogen). Resulting clones were puriﬁed and
sequenced to conﬁrm successful mutagenesis and exclude
polymerase-induced mutations. The mutated HTS1/
pDONR221 entry clone was subsequently recombined into a
Gateway-compatible LEU2-bearing pRS315 destination
vector. Resulting clones were puriﬁed and digested with
BsrGI (New England Biolabs) to conﬁrm successful
recombination.
Two independently generated haploid hts1 strains
(harbouring a pRS316 maintenance vector to express wild-
type HTS1 and URA3) were transformed with a LEU2-
bearing pRS315 vector containing no insert (‘Empty pRS315’
in Fig. 2) or containing a wild-type or mutant HTS1 allele
(Vester et al., 2013). Subsequently, yeast strains were selected
on medium lacking uracil and leucine (Teknova) to select for
the presence of both vectors. For each transformation, four
colonies were grown to saturation in selective medium for
48 h. Next, 10 ml of undiluted and diluted (1:10 and 1:100)
samples from each culture were spotted on plates containing
0.1% 5-ﬂuoroorotic acid (5-FOA) or SD -leu -ura growth
medium (Teknova) and incubated at 30C for 48 h. Survival
was determined by visual inspection of growth. Experiments
were performed using two independently generated HTS1
expression constructs for each allele (designated as ‘A’ and
‘B’ in Fig. 2).
Caenorhabditis elegans plasmids
and strains
Nematode strains were provided by the Caenorhabditis
Genetic Centre. Strains were raised at room temperature on
nematode growth media plates with OP50 Escherichia coli as
the food source per standard protocols (Brenner, 1974).
Plasmids and transgenic worms were constructed as previously
described (Mello et al., 1991; Vester et al., 2013). The human
p.Asp364Tyr mutation was created by PCR-based site directed
mutagenesis into the equivalent C. elegans hars-1 residue
D383Y using the oligonucleotide primers: D383Y_FWD:
TAGCTGCCGGTGGACGATACTAT; and D383Y_REV: AT
AGTATCGTCCACCGGCAGCTA.
Morphological and behavioural
analysis in C. elegans
Quantiﬁcation of motor neuron and behavioural defects were
performed as previously described (Vester et al., 2013).
Quantiﬁcation was performed on the following strains:
EG1285: oxIs12 (Punc-47::GFP; lin15b) X, BEG16: oxIs12
(Punc-47::GFP; lin15b) X; aabEx12 (Punc-25::hars-1
[D383Y], Pmyo-2::mCherry). L4 stage worms were synchro-
nized by bleaching and grown at 20C. Morphological defects
were quantitated in 4100 worms/genotype at each develop-
mental time point. Animals exhibiting at least one aberrant
neuronal process were scored as positive. Behavioural thrash
assays were performed as previously described (Miller et al.,
1996; Vester et al., 2013). At least 40 animals/genotype were
tested. Brieﬂy, single animals were picked to a 35mm agarose-
coated dish ﬁlled with 2ml of M9 media. Animals were
allowed to acclimate for 2min and then a 1-min video was
recorded using a Leica IC80HD camera. The movies were
slowed to one-quarter speed and the total number of body
bends per minute was manually scored ofﬂine using ImageJ
software.
Microscopy
All morphological quantitation was performed on a Leica
DMI6000B compound microscope with a CCD camera
(DFX360, Leica Microsystems Inc.) using a 40 objective.
High-resolution confocal images were obtained on a Nikon
A1R microscope with a 20 and 60 objective (Nikon
Corporation).
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Results
Mutations in HARS are identified
in patients with IPN
Linkage analysis, Sanger sequencing, and whole-exome
sequencing revealed four distinct heterozygous mutations
in HARS in four unrelated families with dominantly
inherited peripheral neuropathy.
Genome-wide linkage analysis in Family A, including
four affected and three unaffected family members, revealed
one chromosomal interval on chromosome 5q tentatively
linked to the disease, with a maximal LOD score of
2.107. All affected individuals, but none of the unaffected
subjects, shared a haplotype consisting of 93 SNP alleles
over a region of 7.9Mb. This interval contained 161 pos-
itional RefSeq genes including HARS, which was con-
sidered as the most plausible candidate gene (Vester
et al., 2013). Sanger-sequencing of HARS revealed the
p.Thr132Ile variant. This variant also segregated in all
additional family members previously not included in the
linkage study. At the same position another amino acid
change p.Thr132Ser was listed in dbSNP database
(rs143473232), this variant is present in 1 of 13 006
chromosomes in the EVS.
In Family B, linkage analysis revealed ﬁve plausible
regions with suggestive but inconclusive linkage (LOD
score 41) on chromosomes 5, 6, 11, 13 and 14.
Searching these ﬁve regions of interest for variants iden-
tiﬁed by whole-exome sequencing in the index patients,
promising variants in six candidate genes were found:
CDC42BPG, KLHDC1, MYH7, PYGL, PCDHB1, and
the p.Pro134His variation in HARS as the most likely
segregating candidate.
In Family C, whole-exome sequencing data ﬁltering
yielded promising variants in 66 genes including a
p.Asp175Glu variant in HARS, which was found to segre-
gate with the disease in the pedigree.
In Family D, linkage analysis including seven affected
and ﬁve healthy individuals delineated six genomic regions
of interest: four on chromosomes 4, 5, 8, 9 (LOD score
2.4) and two located on the X chromosome (LOD score
1.8). Whole-exome sequencing data from two affected
patients combined with linkage analysis revealed only two
possible variants, one in LHX6 and one in HARS. After
conﬁrmation with Sanger sequencing, the variant in LHX6
was excluded because of presence also in a healthy family
member not included in the original linkage analysis, thus
leaving the segregating p.Asp364Tyr variant in HARS as
the only probable disease cause.
All variants detected in HARS (p.Thr132Ile,
p.Pro134His, p.Asp175Glu, p.Asp364Tyr) are in the het-
erozygous state and segregate with disease in all available
family members from Families A–D (Fig. 1). In silico pre-
diction programs classiﬁed all four missense variants as
pathogenic: ‘probably damaging’ (PolyPhen-2) (Adzhubei
et al., 2010), ‘damaging’ (SIFT) (Ng and Henikoff, 2001),
‘disease causing’ (Mutation Taster) (Schwarz et al., 2014)
and ‘high’ (Mutation Assessor) (Reva et al., 2011). The
same apply also for the variant p.Thr132Ser; the prediction
programs assessed it as pathogenic. None of the four HARS
variants are present in dbSNP, the Exome Variant Server, or
1000 genomes database (Supplementary Table 2). No add-
itional HARS mutations were found in a cohort of 62 index
patients with genetically unresolved HMN to which Family
D belonged. Families B, C, and D were part of large whole-
exome sequencing effort tackling a heterogeneous cohort of
128 autosomal dominant families with genetically un-
deﬁned neuropathies (axonal and intermediate CMT and
Figure 2 CMT-associated HTS1 variants decrease yeast cell viability. Haploid hts1 yeast strains were transformed with a vector
containing no insert (pRS315 Empty) or an insert to express wild-type, p.Thr132Ile, p.Thr132Ser, p.Pro134His, p.Asp175Glu or p.Asp364Tyr HTS1
(Supplementary Table 4). Two colonies (indicated by ‘A’ and ‘B’) from transformations with Thr132Ile, Thr132Ser, Pro134His, Asp175Glu or
Asp364Tyr HTS1 are shown. Resulting colonies (undiluted, diluted 1:10, or diluted 1:100) were grown on agar plates containing 0.1% 5-FOA. Note
the severe depletion of growth associated with p.Asp175Glu HTS1 at 1:10 and 1:100 dilutions.
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HMN). Data were analysed using GEMapp (Gonzalez
et al., 2013b) but apart from these three families, no add-
itional HARS mutations were identiﬁed.
Clinical findings
Clinical and electrophysiological ﬁndings in all studied
individuals are summarized in Table 1 and Supplementary
Table 3. Photos of selected patients from Families A and D
are in Supplementary Fig. 1. The phenotype is variable,
with disease onset ranging from early childhood to late
adulthood. Some individuals had clinical signs and electro-
physiological abnormalities without subjective symptoms
(Subjects A-IV.3, A-IV.6, D-IV.2, and D-IV.6). Especially
in Family D, most patients are mildly affected, often only
displaying steppage gait and sensory symptoms/signs at
later stages of the disease (Supplementary Fig. 1). Two
asymptomatic individuals (Subjects D-IV.2 and D-IV.6)
have brisk patellar reﬂexes with absent ankle jerks. Based
on electrophysiological studies, the phenotypes of the
families were classiﬁed as axonal neuropathy in Families
A, C, and D and intermediate neuropathy in Family B.
Four young individuals did not have sensory symptoms/
signs and normal sensory nerve conduction studies consist-
ent with a diagnosis of HMN (Subjects A-V.1, D-IV.2, D-
IV.3 and D-IV.6). Older individuals of the same families
were diagnosed with CMT2.
HTS1 mutations are associated with
decreased cell viability in yeast
Yeast complementation assays have been employed to test
mutations in ARS genes for a loss-of-function effect, includ-
ing p.Arg137Gln in HARS (Antonellis et al., 2006;
Jordanova et al., 2006; McLaughlin et al., 2010; Stum
et al., 2011; Gonzalez et al., 2013a; Vester et al., 2013;
Grifﬁn et al., 2014). To test the functional consequences of
the four HARS missense variants that segregate with dis-
ease (p.Thr132Ile, p.Pro134His, p.Asp175Glu and
p.Asp364Tyr) and one rare variant listed in dbSNP without
diseases association (p.Thr132Ser), we modelled these mis-
sense variants in the yeast orthologue HTS1
(Supplementary Table 4) and independently tested each
mutation for the ability to support yeast cell growth com-
pared to wild-type HTS1 or an empty vector. Mutations in
the text and Fig. 2 are referred to by the position in the
human protein. Brieﬂy, a haploid yeast strain (with the
endogenous HTS1 locus deleted and a maintenance vector
to express wild-type HTS1 and URA3) was transformed
with either a pRS315 vector with no insert (‘Empty
pRS315’ in Fig. 2) or a pRS315 vector harbouring
wild-type, p.Thr132Ile, p.Thr132Ser, p.Pro134His,
p.Asp175Glu, or p.Asp364Tyr HTS1. Yeast cells were
then selected on media containing 5-FOA, which is toxic
to yeast expressing URA3 and therefore selects for
cells that have spontaneously lost the maintenance vector
(Boeke et al., 1987). Only yeast cells expressing a
functional HTS1 allele from pRS315 will grow in this
assay.
Yeast transformed with a wild-type HTS1 expression
vector demonstrated signiﬁcant growth, while those trans-
formed with the empty vector did not (Fig. 2). These data
are consistent with HTS1 being an essential gene (Vester
et al., 2013). Regarding the novel, CMT-associated HARS
mutations described here, yeast expressing p.Thr132Ile,
p.Pro134His and p.Asp364Tyr HTS1 were unable to
grow on 5-FOA media (Fig. 2) indicating that these are
complete loss-of-function alleles. Additionally, yeast
expressing p.Asp175Glu HTS1 showed a signiﬁcant reduc-
tion, but not complete abrogation, of yeast viability com-
pared to wild-type HTS1 (Fig. 2; note pronounced
differences in growth at 1:10 and 1:100 dilutions) indicat-
ing that this is a partial loss-of-function allele. Unlike
CMT-associated HARS mutations, the p.Thr132Ser
HARS variant supported yeast growth to the same extent
as wild-type HARS, indicating that this variant has no
signiﬁcant effect on HARS activity.
p.Asp364Tyr causes late-onset motor
neuron defects and behavioural
impairments in C. elegans
C. elegans was previously established as a model system to
differentiate the pathogenicity of potential mutant hars-1
(the C. elegans orthologue of HARS) variants (Vester
et al., 2013). In C. elegans, 19 GABA motor neurons
innervate body wall muscles and are required for locomo-
tion via reciprocal inhibition (Schuske et al., 2004). These
GABA motor neuron cell bodies reside in the ventral nerve
cord and extend circumferential axons that form the dorsal
nerve cord—these axons are easily visualized with ﬂuores-
cent proteins facilitating visual assessment of axon morph-
ology and integrity (Fig. 3A). To determine if p.Asp364Tyr
expression resulted in morphological and functional tox-
icity to motor neurons, we speciﬁcally expressed the C.
elegans hars-1 (p.Asp364Tyr) transgene in GABA motor
neurons, which were labelled with green ﬂuorescent protein
(GFP). Expression of p.Asp364Tyr caused morphological
neurotoxicity denoted by dorsal and ventral nerve gaps,
axonal blebbing, and severely aberrant axonal processes
that were not present in control animals (Fig. 3B).
Axonal morphological defects increased over time (L4 to
7-day adult) in those animals expressing the p.Asp364Tyr
variant (Fig. 3C). To determine if the axonal pathology
produced behavioural defects, we tested animals in liquid
thrash assays, which measure the ﬁdelity of neuromuscular
motor performance (Miller et al., 1996). Transgenic
animals expressing the p.Asp364Tyr variant exhibited sig-
niﬁcantly decreased thrashing rates compared to control in
4- and 7-day adults, which mirrored the increased axonal
pathology (Fig. 3D). Although p.Asp364Tyr expressing L4
and 1-day adult animals exhibited a signiﬁcant increase in
axonal pathology, there were no overt behavioural defects,
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suggesting p.Asp364Tyr expression imparts a progressive
loss of motor neuron function and neuromuscular coordin-
ation (Fig. 3C and D).
Discussion
The advent of next-generation, high-throughput sequencing
technologies has allowed rapid identiﬁcation of disease-
associated variants. However, these same advances have
caused human geneticists to be increasingly faced with vari-
ants of unknown signiﬁcance in single patients and small
families (Schabhuttl et al., 2014). Several ARS family mem-
bers have been implicated in IPNs; however, the simple
identiﬁcation of a missense variant in a gene encoding
one of these enzymes is not sufﬁcient evidence of pathogen-
icity. To date, mutations in three ARSs (GARS, YARS and
AARS) have strong genetic evidence supporting a role in
dominantly inherited peripheral neuropathy (Antonellis
et al., 2003; Jordanova et al., 2006; Latour et al., 2010;
Zhao et al., 2012). Our study now establishes the same
level of genetic evidence for the role of HARS in IPN.
Previously, a missense variant in histidyl-tRNA synthetase
(p.Arg137Gln HARS) was identiﬁed in a single patient with
late-onset, sensory-predominant axonal neuropathy; how-
ever, segregation studies could not be performed and this
variant was also identiﬁed at a very low rate in the general
population (Vester et al., 2013). Despite demonstrating
a loss of function and dominant toxicity in established
functional assays, the lack of segregation studies and failure
to identify additional unrelated families with IPN and
HARS mutations made it difﬁcult to establish a causal
link between HARS and IPN (Vester et al., 2013). In the
current study, next-generation sequencing was used to iden-
tify four HARS mutations in four large unrelated families
with IPN. All four mutations are missense alterations that
segregate with disease status and that are predicted to be
pathogenic using several in silico tools (Supplementary
Table 2). In the current study no large systematic cohort
screenings have been performed so an accurate estimation
of HARS mutation frequencies is not possible. Based on the
series that were studied we estimate that the frequency is in
the order of 1.6–2.3% (1/62 in HMN cases and 3/128 in
GEMapp). Given the extensive phenotypic diversity asso-
ciated with HARS mutations we expect multiple additional
cases are likely to be identiﬁed in future whole-exome
sequencing studies.
A growing body of evidence suggests that impaired
enzyme function is an important component of ARS-
mediated CMT disease. Fifteen of 19 CMT-associated
mutations in GARS, YARS, and AARS demonstrate loss-
of-function characteristics in aminoacylation assays and/or
in yeast complementation assays. Importantly, all muta-
tions that cause a loss of function in yeast growth assays
also demonstrate loss of tRNA charging in kinetic assays
(Jordanova et al., 2006; McLaughlin et al., 2010, 2012;
Grifﬁn et al., 2014). By using a yeast model to test theT
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function of ARS variants in vivo, we determined that all
four disease-associated HARS variants result in a severe
reduction in yeast viability. In contrast, although affecting
the same residue as p.Thr132Ile, the p.Thr132Ser HARS
variant, which is not associated with disease, complements
loss of endogenous HTS1, indicating that p.Thr132Ser is
not a loss-of-function allele (Fig. 2). This supports the
notion that impaired function is an important component
of ARS-mediated disease pathogenesis. In addition, we used
a C. elegans model to show that over-expression of
p.Asp364Tyr HARS causes morphological and functional
motor deﬁcits, consistent with the dominant IPN phenotype
Figure 3 p.Asp364Tyr (D364Y) motor neuron expression causes axonal pathology and neuromuscular defects in C. elegans. (A)
Diagram of the 19 DD and VD GABA motor neuron cell bodies (green dots), which are located in the ventral nerve cord (VNC), and their
commissural axonal processes. Ventral motor neuron cell bodies extend dorsal circumferential axons forming the dorsal nerve cord (DNC).
Figure adapted with permission from Vester et al. (2013). (B) Whole animal (upper panels) and magnified (lower panels) confocal images of control
oxIs12 [Punc-47::GFP] and oxIs12; hars-1 (D364Y) expressing animals. In control animals, commissural axons (white arrowhead) extend dorsally
from ventral motor neuron cell bodies forming a continuous dorsal nerve cord. Note the homogeneous GFP expression and lack of axonal
blebbing in control animals (lower panel, white arrowhead). Expression of hars-1(D364Y) causes aberrant axonal commissures that fail to reach the
dorsal nerve cord (yellow arrowhead), prominent dorsal nerve cord gaps (yellow arrow), and axonal blebbing (yellow asterisks) not observed in
controls. Scale bar = 50mm. (C) Quantification of aberrant GABA motor neuron axonal commissures in HARS-1 (D364Y) expressing animals
(n5 100 worms/genotype; n = 5 trials/genotype). (D) Quantification of thrash assays in liquid media (n5 40 animals/genotype). Error bars 
SEM, *P5 0.05, Students t-test.
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observed in patients carrying this mutation. This also con-
ﬁrms that yeast and C. elegans data are consistent with the
previously identiﬁed variant (Vester et al., 2013) and in
favour of pathogenicity allowing the use of genetic and
yeast data alone to implicate the remaining alleles.
Phenotypic diversity in IPN is well documented and next
generation sequencing techniques have helped reveal the
allelic heterogeneity of IPN-associated mutations that
may, at least partially, explain the phenotypic variations
observed. Our current study demonstrates the diverse
types of IPN—in terms of presentation, severity and elec-
trophysiology—that are associated with HARS mutations.
Family A is diagnosed with an adult onset CMT2 pheno-
type of moderate severity. Family B on the other hand dis-
plays a more severe disease course with marked slowing of
nerve conduction velocities that are in the range of CMT1
for the older individuals. This ﬁnding suggests a progressive
slowing of nerve conduction velocities. Subject B-III.5 had
positive sensory symptoms under the form of paraesthesia.
In Family C the disease presentation and severity is highly
variable with the male index (Subject C-III.1) presenting a
typical CMT phenotype in adolescence while his mother
(Subject C-II.2) has unusual late onset features with positive
sensory symptoms. Electrophysiology is again in keeping
with CMT2 although the effect of progressive slowing of
nerve conduction velocities seems to be present as well. In
Family D, an initial diagnosis of pure motor axonal neur-
opathy was made in some patients (HMN) but on progres-
sion of the disease in older individuals, clear sensory
symptoms and signs and abnormalities of the sensory
nerve conductions were noted. Follow-up over time will
show if sensory involvement becomes apparent in
Subjects A-V.1, D-IV.2, D-IV.3 and D-IV.6 as well. Most
other neuropathy phenotypes associated with mutations in
the ARSs genes have an axonal electrophysiology with the
exception of DI-CMTC caused by YARS mutations where
a degree of nerve conduction velocity slowing in the inter-
mediate range is described (Jordanova et al., 2006). Even
within the group of axonal neuropathies linked to the ARS
genes clear, variability of the affected nerve ﬁbres is known
with GARS and AARS mutations causing both CMT2 and
HMN phenotypes (Antonellis et al., 2003; Zhao et al.,
2012). For the currently described HARS mutations, no
obvious genotype–phenotype correlations can be made.
The Asp175Gly mutation in HARS is a hypomorphic
allele with a clearly reduced but not completely abolished
yeast colony growth compared to control conditions. Given
the mildly affected individuals in the ﬁrst and second gen-
eration of the corresponding family this raises the question
of a genotype–phenotype correlation. However Subject
C-III.1 has a more typical CMT phenotype in adolescence
so this correlation is certainly not straightforward. At the
same time several individuals in Family A (Subjects A-IV.3
and A-IV.6) and Family D (Subjects D-IV.2 and D-IV.6) are
very mildly affected as well although their respective muta-
tions (Thr132Ile and Asp364Tyr) are complete loss of func-
tion alleles. Based on this observation and also our
extensive previous experience with other ARS genes
(GARS and AARS), we are conﬁdent that the yeast assay
is a robust predictor of disease but does not allow for
strong correlations with disease severity.
ARSs are ubiquitously expressed enzymes that perform
the essential ﬁrst step of protein translation. It is therefore
interesting that mutations in genes encoding these enzymes
have been implicated in tissue-speciﬁc diseases such as
peripheral neuropathy. There is currently a preponderance
of data suggesting that impaired ARS function is a compo-
nent of dominant ARS-related IPN; however, to date only
missense and in-frame deletions have been associated with
these diseases suggesting that the mutant protein must be
expressed. This apparent discrepancy may be explained by
two non-mutually exclusive possibilities. First, as GARS,
AARS, YARS, and HARS holoenzymes function as homo-
dimers, the loss-of-function protein may deplete the
function of the remaining wild-type protein via a
dominant-negative effect (Freist et al., 1999). In this scen-
ario, dramatically reduced ARS function may breach a
threshold of tRNA charging required for protein transla-
tion in axons, leading to the axonal phenotype (Wallen and
Antonellis, 2013). Second, impaired ARS function (i.e.
reduced catalytic activity or decreased tRNA binding)
may be a prerequisite for an as-yet undiscovered toxic
gain-of-function effect; for example, mutant ARS may
now be free to inappropriately bind to axonal RNAs or
proteins (Motley et al., 2010, 2011; Wallen and
Antonellis, 2013). The ﬁrst possibility is supported by the
over 20 loss-of-function mutations identiﬁed in the dimeric
GARS, YARS, AARS and HARS enzymes in patients with
IPN (Wallen and Antonellis, 2013; Grifﬁn et al., 2014) and
the fact that each HARS mutation described here maps to
the catalytic domain of the enzyme. The second possibility
is supported by the apparent lack of a neuropathy pheno-
type in patients with Usher Syndrome that are homozygous
for a presumably hypomorphic HARS mutation
(p.Tyr454Ser) (Puffenberger et al., 2012). However, it is
important to note that patients homozygous or compound
heterozygous for null and/or hypomorphic mutations in
other ARS enzymes do present with a peripheral neur-
opathy (Isohanni et al., 2010; McLaughlin et al., 2010;
Schwartzentruber et al., 2014). While the mechanistic link
between ARS mutations and IPN remains unclear, there is
abundant evidence that reduced ARS function is an import-
ant component of the molecular pathology.
Here we present clinical, genetic and functional data that
implicate HARS mutations in inherited peripheral neur-
opathy. These ﬁndings expand the locus, allelic, and pheno-
typic spectrum of ARS-related human disease and further
support a pathogenic role for these enzymes in diseases of
the peripheral nerve. Future efforts aimed at teasing out the
precise molecular pathology of ARS mutations will be crit-
ical for assessing if improving enzyme function or decreas-
ing the activity of mutant ARS alleles will be relevant
therapeutic strategies for patients with dominant ARS-
related disease.
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